Correct myelination is crucial for the function of the peripheral nervous system. Both positive and negative regulators within the axon and Schwann cell function to ensure the correct onset and progression of myelination during both development and following peripheral nerve injury and repair. The Sox2 transcription factor is well known for its roles in the development and maintenance of progenitor and stem cell populations, but has also been proposed in vitro as a negative regulator of myelination in Schwann cells. We wished to test fully whether Sox2 regulates myelination in vivo and show here that, in mice, sustained Sox2 expression in vivo blocks myelination in the peripheral nerves and maintains Schwann cells in a proliferative non-differentiated state, which is also associated with increased inflammation within the nerve. The plasticity of Schwann cells allows them to re-myelinate regenerated axons following injury and we show that re-myelination is also blocked by Sox2 expression in Schwann cells. These findings identify Sox2 as a physiological regulator of Schwann cell myelination in vivo and its potential to play a role in disorders of myelination in the peripheral nervous system.
INTRODUCTION
Schwann cells (SC) are the myelinating glia of the peripheral nervous system (PNS); they myelinate large diameter axons and provide trophic support for both motor and sensory axons. The transcriptional programmes driving both myelination and the dedifferentiation of SCs following injury have been partially characterised and many positive regulators, such as Krox20 (Egr2), Oct6 (SCIP or Tst1), Sox10 and Nfatc4, have been identified by both in vitro and in vivo analysis. However, there is still little data on the potential negative regulators of myelination in vivo that play roles in both the correctly timed onset of myelination and possibly in the pathology of demyelinating neuropathies of the PNS (Topilko et al., 1994; Svaren and Meijer, 2008; Jaegle et al., 1996; Finzsch et al., 2010; Kao et al., 2009; Jessen and Mirsky, 2008) .
Although the transcription factors Pax3, Jun (cJun) and Sox2, activation of the Notch pathway, and signalling through Erk1/2 and p38 mitogen activated protein (MAP) kinases have been shown to inhibit myelination of SCs in vitro, there is only direct genetic evidence available for Notch signalling, Erk1/2 and p38 activation regulating these processes in vivo (Yang et al., 2012; Parkinson et al., 2008; Harrisingh et al., 2004; Woodhoo et al., 2009; Doddrell et al., 2012; Jessen and Mirsky, 2008; Napoli et al., 2012; Ishii et al., 2016 Ishii et al., , 2013 Roberts et al., 2016) .
The high mobility group (HMG) domain transcription factor Sox2 has been shown in vitro, using SC/dorsal root ganglion (SC/DRG) co-cultures and adenoviral overexpression of Sox2 in SCs, to inhibit the induction of Krox20 and myelination of axons , but a demonstration of the potential inhibitory role of Sox2 in vivo within the intact peripheral nerve has not yet been provided. In order to test the role of Sox2 in vivo, we have made use of a conditional Sox2IRESGFP allele (Lu et al., 2010) , which is activated in a cellspecific manner by crossing with the SC-specific P0-CRE line, and have tested the effects of ongoing Sox2 expression upon PNS myelination and repair. These experiments show, for the first time, that in vivo Sox2 will suppress PNS myelination and re-myelination following injury. In addition, persistent Sox2 expression in the adult nerve is sufficient to induce SC proliferation and an ongoing inflammatory state within the intact peripheral nerve.
RESULTS

Sox2 blocks Krox20-driven expression of myelin-associated proteins
The analysis of mice with a hypomorphic allele of Krox20/Egr2 (Egr2 Lo/Lo ) showed PNS hypomyelination and continued postnatal expression of the Sox2 transcription factor in SCs . This study also showed that high levels of Sox2 in SCs blocked the in vitro induction of Krox20 by cAMP and myelination in SC/DRG co-cultures. Previous analysis of inhibitors of myelination, e.g. Jun, have shown that Jun can both inhibit the induction of Krox20 in SCs as well as prevent the ability of exogenously expressed Krox20 to induce myelinating SC markers. In this way, Jun acts as an inhibitor of myelination both upstream and downstream of Krox20 function . While Sox2 has been shown to block Krox20 induction in SCs by cAMP , we tested whether maintained Sox2 can also inhibit the action of the promyelinating transcription factor Krox20 in inducing myelinating SC markers . In adenoviral co-infection experiments, as expected, Krox20 induced both the expression of myelin protein zero (P 0 ; Mpz) and the myelinating cell marker periaxin in SCs (Parkinson et al., 2003 . Co-expression of Sox2 with Krox20 in SCs showed that Sox2 strongly antagonised Krox20-induced expression of both P 0 and periaxin ( Fig. 1A-I ), confirming, in vitro, that maintained Sox2 expression blocks the myelination programme both upstream and downstream of Krox20 induction in SCs.
Sox2 expression inhibits myelination in vivo
We next tested whether Sox2 can act as an inhibitor of myelination in vivo within the intact nerve. A conditional overexpressing allele for Sox2 (Sox2IRESGFP), inserted into the Rosa26 locus, has been described that, upon CRE-mediated recombination, expresses both Sox2 and enhanced green fluorescent protein (GFP) (Lu et al., 2010) . In order to drive SC-specific expression of Sox2, we used the mP 0 TOTA-CRE (P0-CRE) line (Feltri et al., 1999) to remove the floxed 'stop-cassette' sequence and allow cell-specific expression of Sox2 and GFP in SCs. We have characterised nerves from transgenic CRE+ mice that have either one (Sox2 HetOE ) or both (Sox2 HomoOE ) recombinant Rosa26-Sox2IRESGFP alleles and the effects of Sox2 expression upon PNS myelination and repair.
We first analysed sciatic nerves of mice carrying one copy of the Sox2IRESGFP transgene. Rosa26 wild-type/Sox2IRESGFP/CRE+ mice (Sox2 HetOE ) showed both Sox2 and GFP expression in SCs of the nerve. Sox2 expression in control and Sox2
HetOE nerves was confirmed by western blot and immunolabelling ( Fig. 2I,J ; Fig. S1A-D) . These nerves and controls were analysed at postnatal day (P) 7 and P21 by transmission electron microscopy (TEM) ( Fig. 2A-D) . Although there is no apparent defect at this stage in axonal sorting (SCs appear to make a normal 1:1 relationship with the axons), there is a substantial reduction in myelin thickness at P7 (Fig. 2B ,E) and at P21 (Fig. 2D,G) resulting in an increased average G-ratio (0.71±0.003) for Sox2
HetOE compared with control (0.68± 0.002) at P21. Western blotting of sciatic nerve from control and Sox2
HetOE at both P3 and P7 showed decreased Krox20 as well as reduced myelin proteins P 0 and myelin basic protein (MBP, Fig. 2I ).
We also observed significant increases in the numbers of unmyelinated axons at both P7 and P21 in Sox2
HetOE nerves compared with controls ( Fig. 2F,H) .
Analysing Sox2 HetOE animals at later timepoints, we observed that the myelination in the PNS appeared to return to normal. At P60 there was no significant difference in G-ratio compared with control animals (0.65±0.02 for Sox2
HetOE compared with 0.66±0.02 for controls), nerve morphology of Sox2
HetOE nerves was completely normal at P60 ( Fig. 3L; Fig. S1J -L) and electrophysiology of Sox2
HetOE nerves showed no changes in nerve conduction velocity at P90 compared with controls (Fig. S1I) . We analysed expression of the Sox2IRESGFP transgene in these Sox2
HetOE animals and found that the expression of both Sox2 and GFP was high at P7 but declined from P21 onwards and was undetectable at later time points, either by western blot or immunocytochemistry; this decrease in GFP expression was associated with onset of myelination in the Sox2
HetOE nerves ( Fig. 2J; Fig. S1A -H). We were unable to discern why expression levels of Sox2 and GFP decline in these Sox2
HetOE mice, but it does show that loss of Sox2 overexpression in a hypomyelinated nerve from P21 onwards will allow myelination to proceed such that it appears normal by P60 in the mouse PNS.
Next, we performed crosses to generate animals carrying two copies of the Sox2IRESGFP transgene and examined whether in this case Sox2 expression persisted in the nerve in CRE+ (Sox2 HomoOE ) animals and effects of such expression. Sox2
HomoOE animals showed a similar hypomyelinating phenotype with ongoing Sox2 expression at P7, P14 and P21 time points in CRE+ animals and Sox2 continued to be expressed up to P60, as measured by either immunolabelling or western blot ( Fig. 3A -H,K and data not shown).
P60 adult Sox2 HomoOE animals were smaller in size compared with controls and showed a typical hindlimb clasping when lifted by the tail ( Fig. 3N-P) , indicating a possible reduction of PNS myelination. TEM analysis of P60 Sox2
HomoOE nerves showed hypomyelination within the adult nerve (Fig. 3I,J) , showing that ongoing Sox2 expression will inhibit myelination even at this later time point in vivo. Immunocytochemistry and western blotting of Sox2
HomoOE nerves at both P7 and P60 showed reduced levels of Krox20 and of the myelin proteins P 0 and MBP ( Fig. 3K; Fig. S2A-F,I ). Levels of the Sox10 transcription factor protein, a key driver of myelination (Finzsch et al., 2010; Fröb et al., 2012) , were unchanged at P7, but actually increased in Sox2
HomoOE nerves at P60 (Fig. S2G) , presumably due to increased numbers of SCs within the nerve (see below and Fig. 7) . Corresponding to the reduction in myelin protein expression, a significant increase in the G-ratio and numbers of unmyelinated axons was observed in Sox2 HomoOE nerves at P60 compared with control and Sox2
HetOE animals (Fig. 3L,M) .
More-detailed examination of P7 and P60 Sox2 HomoOE nerves showed a number of additional effects of Sox2 expression upon nerve morphology. At P7, although SCs are making a 1:1 relationship with axons, there is stalling of the ensheathment (Fig. 4A,B) . In addition, at this age, where myelination is observed, we see an apparent lack of compaction in the outer myelin membrane layers of the SCs (Fig. 4D,E) . At P60, semi-thin and cryostat sections of Sox2
HomoOE nerves show reduced myelination, but also evidence of both axonal loss and ongoing myelin breakdown (Fig. 4F ,G,Q-T). Additionally, at P60 we saw highly disorganised Remak bundles within the Sox2
HomoOE nerves, with groups of small diameter axons not separated by SC cytoplasm, in contrast to control nerves, and observed SCs extending abnormal processes and engulfing collagen fibres (Fig. 4H-L ). An examination of basal lamina structure in P60 Sox2
HomoOE nerves with α6 integrin and laminin α2 staining showed an abnormal and diffuse staining pattern in Sox2
HomoOE nerves when compared with controls ( Fig. 4M-P) . Similar behaviour was observed using in vitro SC/DRG myelinating co-cultures with Sox2-overexpressing SCs; 21 days after ascorbic acid addition to trigger myelination, Sox2-overexpressing SCs did not associate correctly with axons, produced many cellular processes and very little myelin when compared with controls (Fig. S3 ).
Sox2 overexpression reduces nerve conduction velocity (NCV), motor function and sensory function
Following on from the molecular characterisation of nerves overexpressing Sox2, we next compared the NCV in control and Sox2
HetOE animals. Analysis of compound action potentials revealed that Sox2
HetOE nerves have significantly decreased NCVs compared with control nerves at P21 ( Fig. 5A ; see Fig. S4C for examples of original electrophysiological recordings), although this had corrected by P90 (Fig. S1I) , consistent with the normal myelination at this timepoint in these animals ( Fig. S1J-L) . Next, motor functional analysis was tested using a rotarod with an increasing speed by recording the latency to fall (Saporta et al., 2012; Wrabetz et al., 2006) . A significantly reduced latency was observed in Sox2
HomoOE mice at both 6 weeks and 8 weeks of age. Although not significant, a slight reduction in latency was observed in Sox2 HetOE mice at 6 weeks and 8 weeks of age (Fig. 5B,C) .
Further analysis of sensory function was carried out using toe pinch ( pressure) and Von Frey filament (light touch) testing. At 6 weeks, toe pinch testing showed a reduction in the ability of Sox2 HomoOE mice to response to pressure stimuli, compared with control and Sox2
HetOE mice (Fig. S4A) . In testing using Von Frey filaments, we found that Sox2
HomoOE mice also had a significantly decreased ability to respond to light touch stimuli compared with control mice (Fig. S4B) . HetOE mouse nerves. (F) There is a significant increase in the proportion of unmyelinated axons greater than 1 µm in diameter in the sciatic nerves of P7 Sox2
HetOE mice compared with controls. (G) N-cadherin is expressed in developing nerve and declines during myelination with a reciprocal upregulation of E-cadherin, but is re-expressed following nerve injury (Crawford et al., 2008; Wanner et al., 2006) . Expression of Sox2 in SCs has been shown to drive relocalisation of N-cadherin, a cell-surface adhesion molecule, and allow SC clustering in the nerve bridge following injury . Such clustering is effected by the formation of adherens junctions through a calcium-dependent homophilic cadherin-cadherin interaction between SCs (Wanner and Wood, 2002) . Immunolabelling of P60 sciatic nerve sections showed a clear increase in N-cadherin levels in SCs from Sox2 HomoOE nerves compared with controls with an apparent cell membrane localisation ( Fig. 6A-D) . Western blotting confirmed an increase in N-cadherin levels in Sox2
HomoOE nerves, as well as increased levels of the Jun transcription factor, a marker of promyelinating SCs (Fig. 6I,J) .
β-Catenin is an N-cadherin binding partner and has been shown to both colocalise at the SC-axon interface to regulate SC polarity (Lewallen et al., 2011) and to positively regulate SC proliferation in SC-DRG co-cultures (Gess et al., 2008) . β-Catenin immunolabelling and western blotting showed slightly raised levels of expression in P60 Sox2
HomoOE nerves in vivo ( Fig. 6E-J) . Corresponding in vitro experiments with rat SCs showed that enforced Sox2 expression alters SC morphology (Fig. S5A,B) , localises both N-cadherin and β-catenin to the SC membrane in a calcium-dependent manner ( Fig. S5C-J) , and increased the levels of both proteins (Fig. S5K) ; interestingly, expression of a 4-hydroxytamoxifen-regulatable Sox2 (Sox2-ER™) protein in 3T3 fibroblasts was sufficient to drive upregulation and membrane localisation of the N-Cadherin protein after the addition of tamoxifen to this heterologous cell type ( Fig. S6A-E ).
SC proliferation is increased by Sox2 expression in vivo
In Sox2
HomoOE mice, we saw increased numbers of SCs within the nerve from P7 onwards ( Fig. 7G,H; Fig. S7 ). To identify whether Sox2 increased SC proliferation in vivo, we immunolabelled P7 and P60 nerve sections with Ki67. The number of GFP/Ki67-positive nuclei was significantly increased in Sox2
HomoOE mice at both P7 and P60 ( Fig. 7A -F,I,J); however, no significant increase in Ki67 staining or nuclei number was detected at time points as early as P3 ( Fig. S7A-E ; data not shown). HetOE and Sox2 HomoOE nerves at P60. Two-sided two-sample Student's t-test; data from n=3 mice of each genotype; *P<0.05, ***P<0.005. (N) Sox2
HomoOE mice (black, on right of picture) were smaller at P60 compared with control animals. (O,P) Sox2
HomoOE animals (P) show hind limb clasping when lifted by the tail, which is characteristic of peripheral hypomyelination, when compared with control littermate (O).
Increased numbers of macrophages in uninjured Sox2-overexpressing nerves
Having observed that increased Sox2 expression maintains SCs in a proliferative non-myelinating state in the adult nerve, and also some myelin breakdown and axonal degeneration, we next tested whether this was associated with any increase in macrophages and other immune cells within the intact nerve. By double labelling for Iba1 and F4/80, we checked macrophage numbers in P7, P21 and P60 control and Sox2
HomoOE nerves, and found a significant increase in the numbers of macrophages within these intact
Sox2
HomoOE nerves at both P21 and P60 ( Fig. 8A-G ). An increase, although not significant, was also found in numbers of CD3-positive T-cells in intact P60 Sox2
HomoOE nerves compared with controls ( Fig. S8 ).
Sox2 over-expression impairs SC remyelination and functional recovery following nerve injury
Although Sox2 re-expression has been shown to drive cell sorting in the nerve bridge following transection injury , it is not known how maintained Sox2 expression in SCs will HomoOE nerves. Two-sided two-sample Student's t-test; data from n=3 mice of each genotype; **P<0.01, ***P<0.005.
affect nerve repair and regeneration in the distal nerve following a crush injury. Thus, we next investigated the effect of maintained Sox2 expression on SC re-myelination up to 21 days post-crush injury (DPI). As Sox2
HomoOE animals show profound hypomyelination even at P60, we used Sox2
HetOE animals for these experiments. As described above, in Sox2
HetOE mice, Sox2 and GFP expression begins to decline at P21 and myelination corrects to produce normal nerve morphology and G-ratios at P60; nerve conduction velocity is also unchanged at P90 in these animals (above and Fig. S1I-L) .
As we observe transgene expression of both Sox2 and GFP at early developmental timepoints in the Sox2
HetOE animals, we hypothesized that following PNS injury the accompanying dedifferentiation of SCs distal to the injury site may be sufficient to cause re-activation of transgenic Sox2 and GFP expression in the Sox2
HetOE animals, allowing us to study effects of ongoing Sox2 expression in a repairing nerve. This idea proved correct and western blot and immunolabelling showed higher levels of Sox2 induction in Sox2
HetOE animals compared with controls at 7 DPI and that Sox2 and GFP expression were maintained at 21 DPI in these animals compared with controls ( Fig. 9A-F ,L,M). Using TEM, we evaluated SC re-myelination by analysing distal nerve sections from control and Sox2
HetOE mice at 21 DPI. Sox2 HetOE sciatic nerves distal to the site of injury were hypomyelinated (Fig. 9G,H) , with a significantly increased average G-ratio of 0.86±0.028 compared with control nerves, which had an average G-ratio of 0.69±0.028 at this timepoint ( Fig. 9I; see Fig. S9A for G-ratio scatter plot). A significant increase in the percentage of unmyelinated axons and a decrease in P 0 protein expression were observed in Sox2
HetOE mouse nerves at 21 DPI (Fig. 9J,M) .
Although numbers of regenerated axons were apparently unchanged, as visualised by neurofilament staining, further analysis of regenerated nerves at 21 DPI did show a significant increase in the axonal diameter of repaired nerves in Sox2
HetOE animals compared with controls ( Fig. S9B) , as well as significantly increased numbers of macrophages still present within the nerve at this timepoint ( Fig. S9C-G) . No significant difference in macrophage numbers was observed between uninjured nerves from control and Sox2
HetOE animals (Fig. S9G ). Having observed that Sox2 overexpression post-injury leads to a marked reduction in SC re-myelination in Sox2
HetOE mice following injury, we next tested functional recovery of these animals. Tests of functional recovery using a Static Sciatic Index (SSI) measurement showed that recovery in Sox2
HetOE mice was significantly reduced up to 21 DPI compared with control mice (Fig. 9K ). This experiment confirmed that, in addition to impairing remyelination, prolonged Sox2 expression in SCs following injury also attenuates functional recovery in these animals.
We next quantified re-myelination by analysing myelin protein reexpression following sciatic nerve injury. Corresponding to TEM analysis (Fig. 9G,H) , western blotting confirmed that continued expression of Sox2 in the SCs of Sox2
HetOE nerves following injury reduced the re-expression of P 0 at 21 DPI in the distal nerve (Fig. 9L,M) .
Analysis of SC proliferation in Sox2
HetOE mice at 21 DPI also showed an ongoing and significantly increased proliferation in the nerve even at this timepoint after injury (Fig. 9N) , once more showing the potential for Sox2 to maintain SCs in an undifferentiated and proliferative state in vivo within the nerve.
DISCUSSION
Within SCs, the onset of myelination is controlled by a network of transcription factors that cooperate to ensure a timely and appropriate ensheathment and myelination of axons (Svaren and Meijer, 2008) . Mutations in many of these factors, such as those in the zinc-finger protein Krox20 (Egr2), cause hypomyelinating neuropathies in both humans and rodent models (Funalot et al., 2012; Baloh et al., 2009; Desmazieres et al., 2008; Arthur-Farraj et al., 2006; Warner et al., 1999 Warner et al., , 1998 . Although there are a number of positive transcriptional regulators of myelination in SCs, such as Krox20, Sox10, Nfatc4 and Oct6, an increasing number of negative regulators of myelination, such as MAP kinase signalling through p38 and ERK1/2 pathways, Notch signalling and the transcription factors Pax3 and Jun, have been shown to block the myelination of SCs (Doddrell et al., 2012; Harrisingh et al., 2004; Woodhoo et al., 2009; Napoli et al., 2012; Yang et al., 2012; Parkinson et al., 2004 Parkinson et al., , 2008 .
The initial description of Sox2 as an inhibitor of PNS myelination came from the finding that mice with a hypomorphic Krox20 (Egr2) allele (Egr2 Lo/Lo ), and thus reduced Krox20 expression, showed hypomyelination and increased expression of Sox2 in SCs. Further experiments, which aimed to determine the function of Sox2 as a negative regulator of myelination have used a virally mediated expression system in vitro. These experiments showed that overexpression of Sox2 in vitro prevents both the induction of myelinating SC markers such as Krox20 and P 0 , and enhanced the proliferation of SCs to the mitogen neuregulin . Although this gives a good indication of Sox2 function, assays of myelination in vitro may not fully reflect the situation in vivo (Lewallen et al., 2011; Golan et al., 2013) . Thus, the aim of this study was to fully characterise the effects of maintained Sox2 expression upon both myelination and functional repair within the intact nerves of the PNS in vivo. In addition, this in vivo approach allows us to measure effects of maintained Sox2 expression in SCs upon immune cell influx into the nerve, both following injury and in the intact nerve.
Our experiments show a strong inhibitory effect of Sox2 on the myelination programme of SCs at all timepoints examined. The expression of myelinating SC markers such as Krox20, myelin basic protein and P 0 are all reduced, and morphological analysis shows a severe hypomyelination of postnatal nerves. Correspondingly, an analysis of SC-specific Sox2 nulls has shown a slight acceleration of early postnatal myelination (M.D. and X.P.D., unpublished), confirming the inhibitory role of Sox2 in controlling developmental myelination. However, in contrast to experiments with SC-specific Jun and p38αMAP kinase nulls (Parkinson et al., 2008; Roberts et al., 2016) , we do not observe a function for Sox2 in the downregulation of myelin proteins following injury. Injury experiments in Sox2-null nerves showed a similar profile of myelin protein loss compared with controls (X.P.D., unpublished). Thus, the role of Sox2 appears to be more important in regulating the onset of myelination both during development and following injury, rather than in the events of SC dedifferentiation following axotomy.
An analysis of other potential Sox2 targets showed, both in vitro and in vivo, that Sox2 decreased mRNA and protein levels of the nectinlike protein Necl4 (also known as Cadm4) in SCs (Fig. S10) . Inhibition 
G,H) There is an increase in the number of SC nuclei in P7 (G) and P60 (H) Sox2
HomoOE sciatic nerves compared with controls. Numbers given are total nuclei per sciatic nerve transverse section. (I,J) There is a significant increase in the number of GFP/Ki67-positive nuclei in P7 (I) and P60 (J) Sox2
HomoOE sciatic nerves. (G-J) Twosided two-sample Student's t-test; data from n=3 mice of each genotype at each time point; *P<0.05, **P<0.01.
of Necl4 function in SCs, either by shRNA knockdown or expression of a dominant-negative form of the protein, prevents normal SC-axon interaction, Krox20 induction and myelination in vitro Golan et al., 2013; Spiegel et al., 2007) , but loss of Necl4 in vivo is associated with focal hypermyelination and a phenotype resembling several CMT subtypes (Golan et al., 2013) . It is therefore unclear at present what role, if any, decreased Necl4 levels may play in the phenotype we observe in our Sox2 overexpressing animals.
Overexpression of the mammalian Lin28 homologue B (Lin28B) RNA-binding protein and reduction in the levels of the let-7 family of microRNAs in SCs has been shown to inhibit peripheral nerve myelination in vivo (Gokbuget et al., 2015) . As Sox2 has been shown to increase Lin28B levels in embryonic stem cells and neural progenitors (Cimadamore et al., 2013; Marson et al., 2008) , we measured Lin28B protein levels in control and Sox2
HomoOE nerves at P60. We do not detect Lin28B expression in either control or Sox2
HomoOE adult nerve (Fig. S2H) ; therefore, seemingly eliminating the Lin28B/let-7 signalling axis as mediating the Sox2-induced hypomyelination.
It is still unclear why the expression of the Sox2IRESGFP transgene declines in the Sox2
HetOE animals up to P21, as the construct is inserted into the Rosa26 locus and the construct also contains a synthetic cytomegalovirus early enhancer/chicken beta actin (CAG) promoter (Lu et al., 2010) ; but these issues of silencing of the transgene expression were not seen in the Sox2 HomoOE animals, allowing us to monitor the effects of Sox2 expression up to P60 in these animals. Analysis of Sox2
HetOE nerves up to P60 allowed us to measure the effects of the removal of Sox2 overexpression in SCs from P21 onwards. In this case, the nerves continued their myelination and by P60 they appeared normally myelinated with G-ratios similar to control nerves, once again underlining a remarkable ability of SCs within the nerve to resume and complete their myelination programme.
The normal myelination observed in P60 Sox2 HetOE nerves and re-activation of Sox2 expression following injury in these animals also allowed us to confirm that Sox2 negatively regulates both developmental myelination and re-myelination following injury, in contrast to some regulators within SCs that have developmental or repair-specific functions Fontana et al., 2012; Kim et al., 2000; Jessen and Mirsky, 2016; Mindos et al., 2017) .
Whether negative regulators of myelination play roles in the pathology of human peripheral neuropathies or mouse models of these conditions has been recently examined. Increased expression of the Jun transcription factor in SCs has been observed in patients with Charcot-Marie-Tooth (CMT) disease or chronic inflammatory demyelinating polyradiculopathy, and in mouse models of CMT (Saporta et al., 2012; Hutton et al., 2011; Hantke et al., 2014; Klein et al., 2014) . Although it has been suggested that abnormal expression of Jun may be involved in the pathology of the hypomyelination seen (Saporta et al., 2012) , recent work using the C3 mouse model of CMT1A showed that Jun expression was actually protective. Genetic removal of Jun in the C3 mouse, which models human CMT1A, led to a progressive loss of myelinated sensory axons and increasing sensory-motor loss (Hantke et al., 2014) . Thus, as opposed to driving the neuropathy in these animals, raised expression of Jun in SCs is a protective mechanism that ameliorates the disease state. Recent reports have shown that levels of Sox2 mRNA are elevated in mouse models of CMT types 1A and 1B (D'Antonio et al., 2013; Giambonini-Brugnoli et al., 2005) , but any potential roles for this increased expression are currently unknown.
The finding of increased macrophage numbers within both the intact Sox2
HomoOE nerve at P60 and within the Sox2 HetOE nerve following injury suggests a role for Sox2 in the control of macrophage entry to the nerve, although it is not clear whether this is a direct effect, or is due to the lack of myelination or the apparent ongoing myelin breakdown and axonal loss seen in the adult P60 Sox2
HomoOE nerves (Fig. 4F,G ). In conclusion, we have identified that Sox2 acts as an in vivo inhibitor of the myelinating phenotype of SCs and have shown new roles for this protein in both controlling the proliferation of SCs and recruitment of macrophages to the nerve.
MATERIALS AND METHODS
Reagents
Adenoviruses expressing Krox20/GFP, Sox2/GFP and GFP control have been previously described Nagarajan et al., 2001; Parkinson et al., 2004 Parkinson et al., , 2008 . Antibodies against Sox2 were from Novus Biological (NB 110-37235SS) for western blotting and from Millipore (AB5603) for immunostaining. Antibodies against myelin basic protein (MBP) (sc-13912), β2A tubulin (sc-134229) and α6 integrin (F6) were from Santa Cruz Biotechnology. Antibodies to N-cadherin (610920), β-catenin (610163) and Jun (610327) were from Becton-Dickinson. Antibodies to Ki67 (Ab15580) and Sox10 (Ab155279) were from Abcam. Krox20 antibody (PRB-236P) was from Covance. Anti-laminin α2 antibody was from Enzo. Antibodies against myelin protein zero (P 0 ), periaxin, Iba1, F4/80 and CD3 were as described previously (Archelos et al., 1993; Gillespie et al., 1994; Mindos et al., 2017; Napoli et al., 2012) . For further details of primary antibodies used, see the supplementary Materials and Methods. Biotinylated HetOE sciatic nerves at 21 DPI. Two-sided two-sample Student's t-test; data from n=3 mice of each genotype. *P<0.05, ***P<0.005.
antibodies, AlexaFluor fluorescently conjugated antibodies and fluorescently conjugated streptavidin were as previously described .
Transgenic mice and genotyping
Transgenic mouse breeding and experiments were carried out according to Home Office regulations under the UK Animals (Scientific Procedures) Act 1986. Ethical approval for experiments was granted by Plymouth University Animal Welfare and Ethical Review Board. To identify effects of Sox2 overexpression in SCs in vivo, we crossed homozygous Rosa26R-Sox2IRESGFP mice (Lu et al., 2010) with P0-CRE (mP 0 -TOTACRE) mice (Feltri et al., 1999) . This generated heterozygous Rosa26 Sox2IRESGFP CRE-positive (+) and CRE-negative (−) offspring. Heterozygous Rosa26 Sox2IRESGFP CRE + animals were then backcrossed with homozygous Rosa26 Sox2IRESGFP CRE -mice to generate heterozygous and homozygous Rosa26R-Sox2IRESGFP CRE -and CRE + mice. CRE + animals carrying one copy of the Rosa26 Sox2IRESGFP transgene are referred to as Sox2
HetOE ; CRE + animals carrying two copies of the Rosa26 Sox2IRESGFP transgene are referred to as Sox2
HomoOE mice. For analysis of both Sox2 HetOE and Sox2 HomoOE mice, age and sex-matched CRE − animals of the same Rosa26 Sox2IRESGFP transgene status are used as controls. For mouse genotyping, genomic DNA was extracted using the HotSHOT method and analysed as previously described (Lu et al., 2010; Feltri et al., 1999; Truett et al., 2000) .
Nerve injury
For nerve crush injury, the right sciatic nerve was compressed using round end forceps, as previously described (Dun and Parkinson, 2015) . The left sciatic nerve was left uninjured. Mice were euthanized at the indicated time, and both uninjured contralateral and injured distal sciatic nerves collected for analysis.
Cell culture and adenoviral/retroviral infection
Rat SCs were prepared from postnatal day 3 rats, as described previously Parkinson et al., 2001) . SCs were infected with GFP/ Krox-20 (GFP/K20) Nagarajan et al., 2001) , control GFP or GFP/Sox2 adenovirus or both GFP/Sox2 and GFP/ K20 (Sox2/K20) adenovirus for 24 h in defined medium (DM) (Jessen et al., 1994) then incubated for a further 24 h in DM before fixing and immunolabelling. For details of DRG/Schwann cell culture and co-culture, retroviral/lentiviral constructs and infection, RNA preparation and semiquantitative PCR, please see the supplementary Materials and Methods.
Immunocytochemistry, immunohistochemistry and western blotting
SCs were cultured on poly L-lysine/laminin-coated glass coverslips as previously described (Jessen et al., 1994) . For immunohistochemical analysis of sections, nerves were fixed in 4% w/v paraformaldehyde and embedded for cryosectioning. All staining, antibodies, counts and confocal and fluorescence microscopy were as described previously Parkinson et al., 2008 Parkinson et al., , 2003 . Anti-MBP (1:100) and anti-Ki67 (1:200) antibodies were diluted in antibody diluting solution with 0.2% Triton X-100 and incubated overnight at 4°C. For western blotting, nerve samples were lysed in SDS buffer and electrophoresed on SDSpolyacrylamide gels Parkinson et al., 2004 Parkinson et al., , 2008 Parkinson et al., , 2003 . β2A tubulin was used as loading control for western blots.
Transmission electron microscopy
Nerves were fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.2), post-fixed in 1% osmium tetroxide, dehydrated and embedded in resin. Semithin sections were cut using a glass knife and stained with Toluidine Blue. Ultra-thin sections were cut and stained with uranyl acetate and lead citrate. Sections were photographed using a JEOL 1200EX or 1400 TEM microscope. For details of electron microscopy analysis of SC/DRG co-cultures and SCs, see the supplementary Materials and Methods. For quantification of the G ratio in intact and injured nerves, axon diameter and fibre (axon+myelin) diameter were measured from 200 axons from each animal using Image J, which allowed for myelin thickness and G-ratio calculation. For quantification of numbers of myelinated/degenerated fibres per field, average counts were made from five separate fields from both P60 control and Sox2
HomoOE nerves.
Functional testing
Motor capacity in 6-and 8-week-old mice was assessed by rotarod analysis. Rotarod training and final testing was as previously described (Saporta et al., 2012; Kuhn et al., 1995) . (Rods accelerated from 2 to 30 rotations per minute over 250 s.) For nerve conduction velocity (NCV) measurements, sciatic nerves from P21 or P90 animals were dissected and placed into a perfusion chamber for 30-45 min before measurements were initiated. During this time the sciatic nerves were incubated at 37°C, and perfused with artificial cerebrospinal fluid (aCSF) as described previously (Fern et al., 1998; Alix and Fern, 2009 ). The distal ends of the sciatic nerves were positioned within an aCSF-filled glass stimulating electrode and compound action potentials (CAP) were induced (Alix and Fern, 2009 ). CAPs were recorded by the second recording aCSFfilled glass electrode surrounding the proximal end of the sciatic nerve (Fern et al., 1998) and displayed using Signal software (Cambridge Electronic Design). NCVs were calculated using two parameters: (1) the length of the stimulated nerve; and (2) the time difference between the start of the stimulus artefact to the peak of the CAP. Measurements of sensory function on control and Sox2
HomoOE animals were performed using Von Fray filament and toe pinch tests; for more details see the supplementary Materials and Methods.
Functional recovery was measured on mice following injury using the static sciatic index (SSI) measurement. Paw print measurements were taken using a video camera from each mouse before surgery (0 days) and up to 21 days following injury to calculate the SSI (Baptista et al., 2007) .
Statistics
For all experiments, n=3 unless otherwise stated. Graphs display the arithmetic mean with error bars representing one standard error of the mean. Statistical analysis was carried out using Student's t-test and P values are used to denote significance: *P< 0.05, **P< 0.01, ***P<0.005.
Owing to small sample sizes (n<5 for most comparisons), how well normality and equal variances fitted the data could not be reliably assessed. Sample size was not predetermined by statistical methods and randomisation was not applied. For functional testing using the SSI, the evaluation was made by an individual blinded to the animal genotype. No samples or data were excluded from the analysis. The n value for each experiment is stated in the appropriate figure legend. Figure 
Supplementary Figures
Sensory Testing
Sensory function testing was carried out on 6 week old mice and assessed using Von Frey Hairs and the response to toe pinching on a minimum of n=3 per genotype.
For Von Frey filament hair testing, mice were placed into a plastic cage on a metal mesh floor and Von Frey filaments ranging from 0.008-10g were applied to the midplantar surface of the right hindpaw (when in contact with the cage lid) for 5-8 seconds. Filaments were applied in ascending order and the smallest filament to induce a foot withdrawal response was considered the threshold stimulus (Vogelaar et al., 2004) . Three recordings were taken over three consecutive days.
For toe pinch testing: The distal part of the lateral three toes were pinched lightly using a pair of forceps. Hind limb withdrawal upon pinch was taken as a positive response. Three measurements were taken over three consecutive days (ArthurFarraj et al., 2012) .
Construction of Sox2ER
TM protein and retroviral infection.
For generation of the 4-hydroxytamoxifen-regulatable Sox2-estrogen receptor fusion protein, (Sox2ER TM ), the Sox2 cDNA was amplified by PCR using sequence specific primers and cloned into the pBP3:hbER TM vector (Garner et al., 2002) . Inclusion of a BamH1 restriction enzyme site, within the primers, at the 5' end of the cDNA and an EcoR1 site at the 3' end allowed the in-frame cloning of the Sox2 cDNA with the estrogen receptor sequence to make the Sox2ER TM fusion protein. The correct sequence of the Sox2 cDNA and in-frame fusion to the estrogen receptor cDNA was verified by DNA sequencing. Development 144: doi:10.1242/dev.150656: Supplementary information Retrovirus was prepared as previously described and Swiss 3T3 fibroblasts infected and selected in puromycin for experiments (Morgenstern and Land, 1991) . Swiss 3T3 cells were grown and selected in DMEM (low glucose) plus 10% donor calf serum containing 2.5 g/ml puromycin. For immunocytochemistry and western blotting experiments, as for Schwann cells, cells were transferred into defined medium (DM) at time zero. M) or ethanol control were added at time zero and cells fixed or lysed 48 or 72 hours later.
Culture of Schwann cells and Adenoviral infection:
Schwann cells were prepared from the sciatic nerve and brachial plexus of post-natal day 3 rats as previously described . Control GFP and GFP/Sox2 adenoviruses have been previously described . For RNA work, cells were lysed 48h after infection for RNA preparation.
Low calcium DM was prepared by substituting normal DMEM media for DMEM containing no calcium chloride.
RNA preparation and semi-quantitative PCR.
Total RNA was prepared from infected rat Schwann cells using a Qiagen RNeasy kit. cDNA. Total mRNA was extracted and first stand cDNA were synthesised with M-MLV reverse transcriptase (Promega) and random hexamer primers (Promega). The following primers were used for RT-PCR. Sox2 (forward 5' AGACGCTCATGAAGAAGGATAAG 3'; reverse 5' GAGCTGGTCATGGAGTTGTACTG 3'), Necl4 (forward 5' AGGGAGGGAGACACTCTGGTGCTG 3'; reverse 5' GTCATAGACCACAAGCACGTAGAG 3') and 18S rRNA (forward 5' Development 144: doi:10.1242/dev.150656: Supplementary information 
